Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Overview of attention for article published in Journal of Clinical Oncology, August 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news: 5 news outlets
policy: 1 policy source
twitter: 48 X users

facebook: 3 Facebook pages
googleplus: 1 Google+ user
reddit: 1 Redditor

Readers on

mendeley: 450 Mendeley

Summary News Policy documents X Facebook Google+ Reddit

So far, Altmetric has seen 3 policy documents that reference this research output.

Entrectinib (Rozlytrek) for ROS1-positive Non-Small Cell Lung Cancer

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Tecentriq

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

Tecentriq for Non-Small Cell Lung Cancer – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 13 Sep 2019

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.